A detailed history of Shulman De Meo Asset Management LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Shulman De Meo Asset Management LLC holds 1,997 shares of LLY stock, worth $1.86 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
1,997
Previous 2,009 0.6%
Holding current value
$1.86 Million
Previous $1.17 Million 32.62%
% of portfolio
0.41%
Previous 0.33%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024

SELL
$592.2 - $792.28 $7,106 - $9,507
-12 Reduced 0.6%
1,997 $1.55 Million
Q4 2023

Jan 11, 2024

SELL
$525.19 - $619.13 $24,158 - $28,479
-46 Reduced 2.24%
2,009 $1.17 Million
Q3 2023

Oct 19, 2023

SELL
$434.7 - $599.3 $18,692 - $25,769
-43 Reduced 2.05%
2,055 $1.1 Million
Q2 2023

Jul 26, 2023

SELL
$350.74 - $468.98 $38,932 - $52,056
-111 Reduced 5.02%
2,098 $983,000
Q1 2023

Apr 14, 2023

SELL
$310.63 - $364.82 $5,280 - $6,201
-17 Reduced 0.76%
2,209 $758,000
Q4 2022

Jan 23, 2023

BUY
$321.55 - $374.67 $643 - $749
2 Added 0.09%
2,226 $0
Q3 2022

Oct 18, 2022

SELL
$296.48 - $337.87 $592 - $675
-2 Reduced 0.09%
2,224 $719,000
Q2 2022

Jul 22, 2022

SELL
$278.73 - $327.27 $19,511 - $22,908
-70 Reduced 3.05%
2,226 $722,000
Q1 2022

Apr 27, 2022

BUY
$234.69 - $291.66 $32,621 - $40,540
139 Added 6.44%
2,296 $657,000
Q4 2021

Jan 28, 2022

BUY
$224.85 - $279.04 $35,076 - $43,530
156 Added 7.8%
2,157 $596,000
Q3 2021

Oct 26, 2021

BUY
$221.6 - $272.71 $443,421 - $545,692
2,001 New
2,001 $462,000
Q2 2021

Jul 21, 2021

SELL
$180.55 - $233.54 $350,989 - $454,001
-1,944 Closed
0 $0
Q1 2021

Apr 26, 2021

BUY
$164.32 - $212.72 $57,347 - $74,239
349 Added 21.88%
1,944 $363,000
Q4 2020

Jan 13, 2021

BUY
$130.46 - $172.63 $208,083 - $275,344
1,595 New
1,595 $269,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $886B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Shulman De Meo Asset Management LLC Portfolio

Follow Shulman De Meo Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shulman De Meo Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Shulman De Meo Asset Management LLC with notifications on news.